資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34607
|
| 標題: | The Association of Erythropoietin and Age-Related Macular Degeneration in Hemodialysis Patients: A Nationwide Population-Based Cohort Study |
| 作者: | Huang, Evelyn-Jou-Chen
Sung, Fung-Chang
Hung, Peir-Haur
Muo, Chih-Hsin
Wu, Meei-Maan
Yeh, Chih-Ching |
| 貢獻者: | Taipei Medical University
Taipei Medical University Hospital
Taipei Medical University
China Medical University Taiwan
China Medical University Taiwan
China Medical University Hospital - Taiwan
Asia University Taiwan
Department of Applied Life Science and Health, Chia Nan University of Pharmacy & Science
China Medical University Taiwan
Taipei Medical University
Taipei Medical University
Taipei Medical University
China Medical University Taiwan
Taipei Medical University
Taipei Municipal WanFang Hospital |
| 關鍵字: | chronic kidney-disease
stage renal-disease
risk-factors
eye disease
protects
retina
anemia
cells
serum |
| 日期: | 2022 |
| 上傳時間: | 2023-12-11 14:00:29 (UTC+8) |
| 出版者: | MDPI |
| 摘要: | This population-based retrospective cohort study investigated the effectiveness of erythropoietin (EPO) treatment in reducing the risk of age-related macular degeneration (AMD) in hemodialysis patients, using the National Health Insurance Research Data of Taiwan. From the database, we identified 147,318 end-stage renal disease (ESRD) patients on hemodialysis who had been diagnosed in 2000-2014 to establish the propensity-score-matched EPO user cohort and non-EPO user cohort with equal sample size of 15,992. By the end of 2016, the cumulative incidence of AMD in EPO users was about 3.29% lower than that in non-EPO users (Kaplan-Meier survival p < 0.0001). The risk of AMD was 43% lower in EPO users than in non-EPO users, with an adjusted hazard ratio (aHR) of 0.57 (95% confidence interval (CI) = 0.51-0.64) estimated in the multivariate Cox model. A significant negative dose-response relationship was identified between the EPO dosage and the risk of AMD (p < 0.0001). Another beneficial effect of EPO treatment was a reduced risk of both exudative AMD (aHR = 0.48, 95% CI = 0.40-0.61) and non-exudative AMD (aHR = 0.61, 95% CI = 0.53-0.69), also in similar dose-response relationships (p < 0.0001). Our findings suggest that EPO treatment for hemodialysis patients could reduce AMD risk in a dose-response relationship. |
| 關聯: | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.23, n.17, 9634 |
| 顯示於類別: | [生活保健科技系] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| ijms23179634.pdf | | 601Kb | Adobe PDF | 183 | 檢視/開啟 | | index.html | | 0Kb | HTML | 323 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
